Life Sciences Fund Amsterdam

The firm sources primarily through technology transfer offices at Dutch research universities and academic medical centers, notably those in the Amsterdam-Leiden-Utrecht triangle. It also reviews corporate divestiture opportunities from the Netherlands' multinational pharmaceutical and medtech base. This proximity-driven model gives it early access to spin-outs before they reach pan-European venture syndicates.

The mandate covers seed and start-up rounds, late-stage expansion capital, and corporate divestitures. Seed-stage participation typically involves the firm acting as a first institutional check alongside university seed funds and angel investors. Expansion rounds serve existing portfolio companies moving toward regulatory milestones or market entry.

The primary focus is the Amsterdam-Leiden-Utrecht corridor, which hosts the highest concentration of life science spin-out activity in the country. The firm has selectively placed capital in Flanders and the Nordic region, though no dedicated satellite offices exist outside Amsterdam.

Paul Kloppenborg serves as Investment Manager and is the named principal associated with the firm's deal execution. The broader team is compact, operating from a single Amsterdam office without a publicly disclosed investment committee structure.

The approach is hands-on: the firm typically takes board observer seats, provides introductions to clinical key opinion leaders in European academic medicine, and works directly with founders on operational planning. The small portfolio size enables a level of engagement that larger funds cannot match at equivalent check sizes.

The firm invests directly into companies, not through fund-of-funds allocations. It leads or co-leads seed rounds and participates in syndicated venture rounds alongside regional development agencies and specialist health-tech investors.

No explicit exclusion list has been published. Given the firm's size, geography, and academic sourcing model, large-late-stage therapeutics companies requiring hundred-million-euro clinical trials or pure service businesses without proprietary technology are inconsistent with the observed mandate.